Coherus Oncology, Inc. CHRS

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis t

Moby summary of Coherus Oncology, Inc.'s Q2 2026 earnings call

Coherus Oncology Inc (CHRS) reports 15% LOQTORZI sales growth and advancing oncology pipeline, while managing significant cash reduction and legacy liabilities.

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter 2026, and pr

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the

– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripali

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce the appointment of Michael A. Fleming to the board of directors of the Company.

The latest analyst coverage could presage a bad day for Coherus Oncology, Inc. ( NASDAQ:CHRS ), with the analysts...

Moby summary of Coherus Oncology, Inc.'s Q1 2026 earnings call

Coherus Oncology Inc (CHRS) reports a 61% year-over-year increase in LOQTORZI sales, bolstered by strategic partnerships and a successful equity offering, despite weather-related challenges.

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference ca